Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine, AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-21-001141.pdf
0001558370-21-001141.rtf
0001558370-21-001141.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001558370-21-001147.pdf
0001558370-21-001147.rtf
0001558370-21-001147.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-21-001228.pdf
0000080255-21-001228.rtf
UPLOAD

UPLOAD

 View HTML
0000000000-21-001734.pdf
0000000000-21-001734.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001104659-21-017599.pdf
0001104659-21-017599.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-21-000872.pdf
0000315066-21-000872.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000902219-21-000079.pdf
0000902219-21-000079.rtf
0000902219-21-000079.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000834237-21-002930.pdf
0000834237-21-002930.rtf
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-21-000686.pdf
0001179110-21-000686.rtf
0001179110-21-000686.xls
CORRESP

CORRESP

 View HTML
0001558370-21-000203.pdf
0001558370-21-000203.rtf